Adagrasib
Brand names: Krazati · Active ingredient: Adagrasib
In short: KRAZATI, as a single-agent, is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test , who have received at least one prior systemic therapy. This indication is approved under acce
What is Adagrasib used for?
KRAZATI, as a single-agent, is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test , who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) . Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial.
Adagrasib dosage
Select patients for treatment of locally advanced or metastatic NSCLC with KRAZATI based on the presence of KRAS G12C mutation in plasma or tumor specimens . If no mutation is detected in a plasma specimen, test tumor tissue.
Information on FDA-approved tests for the detection of a KRAS G12C mutation is available at: https://www.fda.gov/CompanionDiagnostics
The recommended dosage of KRAZATI is 600 mg orally twice daily until disease progression or unacceptable toxicity.
Take KRAZATI at the same time every day with or without food . Swallow tablets whole. Do not chew, crush or split tablets.
If vomiting occurs after taking KRAZATI, do not take an additional dose. Resume dosing at the next scheduled time.
If a dose is inadvertently missed, it should be skipped if greater than 4 hours have elapsed from the expected dosing time. Resume dosing at the next scheduled time.
Recommended dose reductions for adverse reactions for use of KRAZATI are outlined in Table 1. If adverse reactions occur, a maximum of two dose reductions are permitted. Permanently discontinue KRAZATI in patients who are unable to tolerate 600 mg once daily.
Dose Reduction | Dosage
First dose reduction | 400 mg twice daily
Second dose reduction | 600 mg once daily
The recommended dosage modifications for adverse reactions are provided in Table 2.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ILD = Interstitial Lung Disease; ULN = upper limit of normal
Adverse Reaction | Severity
Grading defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. | Dosage Modification
Nausea or vomiting despite appropriate supportive care (including anti-emetic therapy)
| Grade 3 or 4 | •Withhold KRAZATI until recovery to ≤ Grade 1 or return to baseline.
•Resume KRAZATI at the next lower dose level.
Diarrhea despite appropriate supportive care (including anti-diarrheal therapy)
| Grade 3 or 4 | •Withhold KRAZATI until recovery to ≤ Grade 1 or return to baseline.
•Resume KRAZATI at the next lower dose level.
QTc Interval Prolongation
| QTc absolute value greater than 500 ms or Greater than an increase of 60 ms from baseline | •Withhold KRAZATI until QTc interval less than 481 ms or return to baseline.
•Resume KRAZATI at the next lower dose level.
Torsade de pointes, polymorphic ventricular tachycardia or signs or symptoms of serious or life-threatening arrhythmia | •Permanently discontinue KRAZATI
Hepatotoxicity
| Grade 2AST or ALT | •Decrease KRAZATI to the next lower dose level.
Grade 3 or 4AST or ALT | •Withhold KRAZATI until recovery to ≤ Grade 1 or return to baseline.
•Resume KRAZATI at the next lower dose level. …
How to take Adagrasib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Gastrointestinal Adverse Reactions
Advise patients that KRAZATI can cause severe gastrointestinal adverse reactions and to contact their healthcare provider for signs or symptoms of severe or persistent gastrointestinal adverse reactions .
QTc Interval Prolongation
Advise patients that KRAZATI can cause QTc interval prolongation and to contact their healthcare provider for signs or symptoms of arrhythmias .
Hepatotoxicity
Advise patients that KRAZATI can cause hepatotoxicity and to immediately contact their healthcare provider for signs or symptoms of liver dysfunction .
Interstitial Lung Disease (ILD)/Pneumonitis
Advise patients that KRAZATI can cause ILD / pneumonitis and to contact their healthcare provider immediately for new or worsening respiratory symptoms .
Drug Interactions
Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products .
Missed Dose
If a dose of KRAZATI is missed by greater than 4 hours, resume dosing at the next scheduled time . …
Warnings & precautions
Do not take this medicine if: None.
KRAZATI can cause severe gastrointestinal adverse reactions.
In the pooled safety population , who received single-agent KRAZATI, serious gastrointestinal adverse reactions observed were gastrointestinal bleeding in 3.8% including 0.8% Grade 3 or 4, gastrointestinal obstruction in 1.6% including 1.4% Grade 3 or 4, colitis in 0.5% including 0.3% Grade 3, ileus in 0.5%, and stenosis in 0.3%. In addition, nausea, diarrhea, or vomiting occurred in 89% of 366 patients, including 9% Grade 3. Nausea, diarrhea, or vomiting led to dosage interruption or dose reduction in 29% of patients and permanent discontinuation of adagrasib in 0.3%.
Monitor and manage patients using supportive care, including antidiarrheals, antiemetics, or fluid replacement, as indicated. Withhold, reduce the dose, or permanently discontinue KRAZATI based on severity .
KRAZATI can cause QTc interval prolongation, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death.
In the pooled safety population who received single-agent KRAZATI, 6% of 366 patients with at least one post-baseline electrocardiogram (ECG) assessment had an average QTc ≥ 501 msec and 11% of patients had an increase from baseline of QTc > 60 msec. KRAZATI causes concentration-dependent increases in the QTc interval .
Avoid concomitant use of KRAZATI with other products with a known potential to prolong the QTc interval . Avoid use of KRAZATI in patients with congenital long QT syndrome and in patients with concurrent QTc prolongation. …
Adagrasib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
•Gastrointestinal Adverse Reactions
•QTc Interval Prolongation
•Hepatotoxicity
•Interstitial Lung Disease (ILD)/Pneumonitis
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to adagrasib as a single agent at 600 mg orally twice daily in 366 patients with NSCLC and other solid tumors enrolled in KRYSTAL-1 and KRYSTAL-12 (NCT04685135), respectively. Among 366 patients who received adagrasib, 39% of patients were exposed for 6 months or longer and 12% were exposed for greater than one year. In this pooled safety population, the most common (≥ 25%) adverse reactions were nausea (70%), diarrhea (69%), vomiting (57%), fatigue (55%), musculoskeletal pain (38%), hepatotoxicity (37%), renal impairment (33%), edema (30%), dyspnea (26%), and decreased appetite (29%). …
Drug interactions
Strong CYP3A4 Inducers
Avoid concomitant use of KRAZATI with strong CYP3A inducers.
Adagrasib is a CYP3A4 substrate. Concomitant use of KRAZATI with a strong CYP3A inducer reduces adagrasib exposure , which may reduce the effectiveness of KRAZATI.
Strong CYP3A4 Inhibitors
Avoid concomitant use of KRAZATI with strong CYP3A inhibitors until adagrasib concentrations have reached steady state (after approximately 8 days).
Adagrasib is a CYP3A4 substrate. If adagrasib concentrations have not reached steady state, concomitant use of a strong CYP3A inhibitor will increase adagrasib concentrations, , which may increase the risk of KRAZATI adverse reactions.
Sensitive CYP3A Substrates
Avoid concomitant use of KRAZATI with sensitive CYP3A substrates unless otherwise recommended in the Prescribing Information for these substrates.
Adagrasib is a CYP3A inhibitor. Concomitant use with KRAZATI increases exposure of CYP3A substrates , which may increase the risk of adverse reactions related to these substrates.
Sensitive CYP2C9 Substrates
Avoid concomitant use of KRAZATI with sensitive CYP2C9 substrates where minimal concentration changes may lead to serious adverse reactions unless otherwise recommended in the Prescribing Information for these substrates.
Adagrasib is a CYP2C9 inhibitor. …
About this medicine
Adagrasib is an irreversible inhibitor of KRAS G12C and belongs to the RAS GTPase family. The molecular formula is C32H35ClFN7O2 and the molecular weight is 604.1 g/mol. The chemical name is {(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]- methoxy}-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl}acetonitrile. Adagrasib has the following chemical structure:
Adagrasib is a crystalline solid. The solubility of adagrasib in the aqueous media decreases over the range pH 1.2 to 7.4 from > 262 mg/mL to < 0.010 mg/mL.
KRAZATI (adagrasib) tablets for oral administration contain 200 mg of adagrasib. The following are inactive ingredients: colloidal silicon dioxide, crospovidone, magnesium stearate (vegetable sourced), mannitol, and microcrystalline cellulose. The tablet film coating contains hypromellose, maltodextrin, medium chain triglycerides (vegetable sourced), polydextrose, talc, and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0b8bf078-34c2-4f45-9012-38a8ac082b01. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate